Company: RNAC
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001453687-25-000099
Chunk: 97

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part II, Item 6
Chunk 97
---
 Act of 2002---Filed herewith31.2Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002---Filed herewith32.1Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002---Furnished herewith101.INSInline XBRL Instance Document (the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document)---Filed herewith101.SCHInline XBRL Taxonomy Extension Schema Document---Filed herewith101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document---Filed herewith101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document---Filed herewith101.LABInline XBRL Taxonomy Extension Label Linkbase Document---Filed herewith

42

Table of Contents

101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document---Filed herewith104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)---Filed herewith

* Certain annexes, schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.    

43

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.

 CARTESIAN THERAPEUTICS, INC.  Date: August 7, 2025By:/s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer, and Director(Principal Executive Officer)  Date: August 7, 2025By:/s/ Blaine Davis Blaine Davis Chief Financial Officer(Principal Financial Officer)

44